Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azithromycin PK in Lung Tissue (SR vs IR)
NCT00644176Phase 2Completed
- Sponsor
- Pfizer
- Start
- Nov 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of azithromycin in bacterial infection (2 arms), sponsored by Pfizer. Primary endpoints: Azithromycin Cmax, Tmax, AUC72, AUClast, AUC24 in serum at 72 hours and Azithromycin Cmax, Tmax, AUC72, AUC24 in epithelial lining fluid and alveolar cells at 72 hours. Started Nov 2004; status: completed.
02
Drugs
azithromycin
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT00644176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00644176.